Bio-Rad Unveils Vericheck ddPCR™ Empty-Full Capsid Kit for Accurate AAV Vector Characterization

Bio-Rad Laboratories has announced the release of the Vericheck ddPCR™ Empty-Full Capsid Kit, designed to streamline the assessment of AAV (adeno-associated virus) vectors for gene therapy applications. This new kit, powered by Bio-Rad’s Droplet Digital™ PCR technology, enables researchers to determine capsid titer, genome titer, and the percentage of full capsids in both purified and crude lysate AAV samples.

AAV vectors are crucial in gene therapy, but their production often results in impurities such as partial or empty capsids. These impurities can affect therapeutic efficacy and trigger immune responses. The Vericheck ddPCR Kit helps researchers address this by delivering precise, reproducible results that assist in the optimization of AAV vector characterization and quality control.

Key Features of the Vericheck ddPCR Empty-Full Capsid Kit:

• Accurate measurement of capsid titer, genome titer, and percentage of full capsids
• Suitable for use with both purified and crude lysate AAV samples
• High-throughput capabilities for streamlined gene therapy development
• Designed to comply with regulatory standards
• Cost-effective and easy to integrate into existing workflows

This innovative solution supports the advancement of safe and effective gene therapies by providing robust AAV vector quality assessments. Bio-Rad’s commitment to advancing life sciences is reflected in this latest addition to its portfolio.